Current Assets
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value
Edwards Lifesciences AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value increased by 432.2% to $435.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5341.3%, from $8.00M to $435.30M. Over 4 years (FY 2021 to FY 2025), AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value shows a downward trend with a -52.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026May 6, 2026
Metric ID:
afs_trading_securities_unrealized_loss_lt_12m_fvHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $382.00M | $582.70M | $1.63B | $1.61B | $1.54B | $1.24B | $353.90M | $100.50M | $85.10M | $21.40M | $35.20M | $12.20M | $5.10M | $3.60M | $8.40M | $8.00M | $8.70M | $11.30M | $81.80M | $435.30M |
| QoQ Change | — | +52.5% | +180.2% | -1.3% | -4.3% | -19.4% | -71.5% | -71.6% | -15.3% | -74.9% | +64.5% | -65.3% | -58.2% | -29.4% | +133.3% | -4.8% | +8.8% | +29.9% | +623.9% | +432.2% |
| YoY Change | — | — | — | — | +303.5% | +113.1% | -78.3% | -93.8% | -94.5% | -98.3% | -90.1% | -87.9% | -94.0% | -83.2% | -76.1% | -34.4% | +70.6% | +213.9% | +873.8% | >999% |
Range$3.60M – $1.63B
CAGR+2.8%
Avg YoY Growth+380.4%
Median YoY Growth-77.2%
Current Streak4 quarters growth
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's afs and trading securities - unrealized loss position (<12 months) fair value?
- Edwards Lifesciences (EW) reported afs and trading securities - unrealized loss position (<12 months) fair value of $435.30M in Q1 2026.
- How has Edwards Lifesciences's afs and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
- Edwards Lifesciences's afs and trading securities - unrealized loss position (<12 months) fair value increased by 5341.3% year-over-year, from $8.00M to $435.30M.
- What is the long-term trend for Edwards Lifesciences's afs and trading securities - unrealized loss position (<12 months) fair value?
- Over 4 years (2021 to 2025), Edwards Lifesciences's afs and trading securities - unrealized loss position (<12 months) fair value has grown at a -52.7% compound annual growth rate (CAGR), from $1.63B to $81.80M.